ReviewPharmaceutics2024
Recent Advances in Porphyrin-Based Covalent Organic Frameworks for Synergistic Photodynamic and Photothermal Therapy.
Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Porphyrin-Based Porous Materials for Antibacterial Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Assessment of Double-Hybrid Functionals for the Vertical Excitation Energies of Porphyrins.Molecules (Basel, Switzerland) · 2026Article
- The Influence of the Central Metal (Zn) in the Porphyrin Skeleton on the Mechanism Induced by Photodynamic Therapy.Cancers · 2026Review
- Smart covalent organic frameworks in cancer sensing and imaging: opportunities, challenges, and translational prospects.Medical oncology (Northwood, London, England) · 2026Review
- Recent advances in photodynamic therapy systems based on pillar[n]arene host-guest chemistry.Frontiers in chemistry · 2026Review
- Molecularly engineered BODIPY photosensitizers for combined cancer phototherapy and immunotherapy.Frontiers in pharmacology · 2026Review
- Intelligent CpG nanoplatforms for targeted cancer immunotherapy and immune remodeling.Frontiers in pharmacology · 2026Review
- Advances in porphyrin-based photosensitizers for photodynamic therapy of A549 lung cancer.Frontiers in pharmacology · 2026Review
- Nanomaterial-Based Photothermal Therapy for Inflammatory Diseases: Intervention Strategies, Synergistic Effects, and Future Challenges.International journal of nanomedicine · 2026Review
- Biomedical applications and perspectives of two-dimensional porphyrin-based MOFs.Frontiers in pharmacology · 2026Review
- Biomolecule-Photosensitizer Conjugates: A Strategy to Enhance Selectivity and Therapeutic Efficacy in Photodynamic Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Nanotechnology-Enabled Combination Therapies and Diagnostic Innovation: An Integrative Overview of Recent Advances.Pharmaceutics · 2025Article
- Nanoscale Porphyrin-Based Metal-Organic Frameworks for Enhanced Radiotherapy-Radiodynamic Therapy: A Comprehensive Review.Pharmaceutics · 2025Review
- Hybrid Nanoplatforms Based on Photosensitizers and Metal/Covalent Organic Frameworks for Improved Cancer Synergistic Treatment Nano-Delivery Systems.Molecules (Basel, Switzerland) · 2025Review
- Recent Advances in Glutathione Depletion-Enhanced Porphyrin-Based nMOFs for Photodynamic Therapy.Pharmaceutics · 2025Review
- Covalent organic frameworks for cancer immunotherapy: mechanisms, applications, and prospects.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Porphyrin's excellent biocompatibility and modifiability make it a widely studied photoactive material. However, its large π-bond conjugated structure leads to aggregation and precipitation in physiological solutions, limiting the biomedical applications of porphyrin-based photoactive materials. It has been demonstrated through research that fabricating porphyrin molecules into nanoscale covalent organic frameworks (COFs) structures can circumvent issues such as poor dispersibility resulting from hydrophobicity, thereby significantly augmenting the photoactivity of porphyrin materials. Porphyrin-based COF materials can exert combined photodynamic and photothermal effects, circumventing the limitations of photodynamic therapy (PDT) due to hypoxia and issues in photothermal therapy (PTT) from heat shock proteins or the adverse impact of excessive heat on the protein activity of normal tissue. Furthermore, the porous structure of porphyrin COFs facilitates the circulation of oxygen molecules and reactive oxygen species and promotes sufficient contact with the lesion site for therapeutic functions. This review covers recent progress regarding porphyrin-based COFs in treating malignant tumors and venous thrombosis and for antibacterial and anti-inflammatory uses via combined PDT and PTT. By summarizing relevant design strategies, ranging from molecular design to functional application, this review provides a reference basis for the enhanced phototherapy application of porphyrin-based COFs as photoactive materials. This review aims to offer valuable insights for more effective biomedical applications of porphyrin-based COFs through the synthesis of existing experimental data, thereby paving the way for their future preclinical utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.